Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Breast Cancer With Low Expression of HER2”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02491892
What this trial is testing

Pertuzumab in Participants With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 79
Testing effectiveness (Phase 2)Looking for participantsNCT06656624
What this trial is testing

Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)

Who this might be right for
Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 190
Testing effectiveness (Phase 2)UnknownNCT05845138
What this trial is testing

SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

Who this might be right for
Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 116
Not applicableNot Yet RecruitingNCT07389200
What this trial is testing

Application of Multimodal MRI-based Radiomics in Histological Grading and Prognostic Assessment of Breast Cancer

Who this might be right for
Breast CancerBreast Cancer With Low to Intermediate HER2 Expression
Hao Xu 400
Large-scale testing (Phase 3)Study completedNCT01479244
What this trial is testing

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

Who this might be right for
Breast Cancer With Low to Intermediate HER2 Expression
Galena Biopharma, Inc. 758
Testing effectiveness (Phase 2)Looking for participantsNCT07497386
What this trial is testing

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Who this might be right for
Unresectable Locally Recurrent Breast CancerUnresectable Locally Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 150
Testing effectiveness (Phase 2)Study completedNCT03321981
What this trial is testing

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Who this might be right for
Breast Cancer Metastatic
Merus B.V. 105
Testing effectiveness (Phase 2)Looking for participantsNCT06439771
What this trial is testing

Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd. 180
Testing effectiveness (Phase 2)UnknownNCT06000033
What this trial is testing

Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Qilu Hospital of Shandong University 35
Early research (Phase 1)Study completedNCT04147819
What this trial is testing

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

Who this might be right for
Cancers With HER2 Expression
Bayer 14
Not applicableNot Yet RecruitingNCT07035353
What this trial is testing

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Who this might be right for
HER2 OverexpressionAdvanced Stage Breast CancerLow Expression of HER2
Tianjin Medical University Cancer Institute and Hospital 200
Testing effectiveness (Phase 2)UnknownNCT05953168
What this trial is testing

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 69